Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Geraldine Martineau"'
Autor:
Emmanuelle Bompas, Geraldine Martineau, Remy Delva, Isabelle Borget, Stéphane Culine, Giulia Baciarello, Groupe d’Etude des Tumeurs Uro-Genitales (Getug)., Charlotte Greilsamer, Philippe Barthélémy, Raffaele Ratta, Mathilde Deblock, Karim Fizazi, Florence Joly, Gwenaelle Gravis, Philippe Beuzeboc, Caroline Cheneau, J. F. Berdah, Youssef Tazi, Thierry Nguyen Tan Hon, Marine Gross-Goupil, Aude Flechon, Aline Maillard
Publikováno v:
European Urology. 81:234-240
Background The taxanes docetaxel and cabazitaxel prolong overall survival for men with metastatic castration-resistant prostate cancer (mCRPC), with cabazitaxel approved in the postdocetaxel setting only. Recent data suggest they have similar efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc3f5f87bba3baaa685a8a0b058be50e
https://doi.org/10.1016/j.eururo.2021.10.016
https://doi.org/10.1016/j.eururo.2021.10.016
Autor:
Elisabeth Carola, Séverine Guiu, Olivier Tredan, Florence Dalenc, Geraldine Martineau, Laurence Venat Bouvet, Hervé Bonnefoi, Delphine Mollon, Christelle Levy, Marie Ange Mouret Reynier, Florence Lerebours, Mahasti Saghatchian, Marina Pulido, Anthony Gonçalves, Gaëtan MacGrogan
Publikováno v:
Cancer Research. 81:PS12-05
Background: Triple negative breast cancer (TNBC) is an heterogeneous disease and encompasses at least 4 subtypes. One of these expresses the androgen receptor (AR). Several prospective trials demonstrated antitumour efficacy with anti-androgen treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8639417e31b5718726ed32e5bb8d1946
https://doi.org/10.1158/1538-7445.sabcs20-ps12-05
https://doi.org/10.1158/1538-7445.sabcs20-ps12-05
Autor:
Thomas Bachelot, Isabelle Desmoulins, Camille Chakiba, Florence Dalenc, Audrey Mailliez, Lise Roca, Véronique Haddad, Anthony Gonçalves, N. Dohollou, Philippe Follana, Séverine Guiu, Frederic Bigot, Geraldine Martineau, Suzette Delaloge, Judith Balmaña, Dominique Genet
Publikováno v:
Cancer Research. 81:OT-13
Background: Olaparib is a PARP inhibitor that has shown high response rates and clinical activity in patients with advanced HER2-negative breast cancer (BC) and a germline BRCA1 and BRCA2 mutation. There is also evidence of cellular sensitivity to PA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b09fe519e21db07f2f53b95c5c8a350
https://doi.org/10.1158/1538-7445.sabcs20-ot-13-05
https://doi.org/10.1158/1538-7445.sabcs20-ot-13-05
Autor:
Gedske Daugaard, R. Janssen, A.J. van de Wouw, Karim Fizazi, Aline Maillard, Diego Tosi, Carmen Balana, Geraldine Martineau, R. Morales Barrera, Elodie Vauleon, Bruno Chauffert, D. Allouache, Stéphane Culine, G. Soler, Loic Chaigneau, Giulia Baciarello, Catherine A. Schnabel, F. Losa Gaspa, Isabelle Borget, Nicolas Penel
Publikováno v:
Annals of Oncology. 30:v851
Background CUP are heterogeneous tumors that share the unique characteristic of metastases with no identifiable origin. The outcome of patients (pts) with CUP is poor despite empiric chemotherapy that has activity against a wide variety of neoplasms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3d130057b4e86c8638e9210aee78eb7
https://doi.org/10.1093/annonc/mdz394
https://doi.org/10.1093/annonc/mdz394
Autor:
Thierry Nguyen Tan Hon, Isabelle Borget, J. F. Berdah, Remy Delva, Florence Joly, Youssef Tazi, Marine Gross-Goupil, Stéphane Culine, Aude Flechon, Tifenn Lharidon, Caroline Cheneau, Emmanuelle Bompas, Karim Fizazi, Gwenaelle Gravis, Philippe Beuzeboc, Geraldine Martineau, Christine Theodore, Giulia Baciarello, Philippe Barthélémy, Mathilde Deblock
Publikováno v:
Journal of Clinical Oncology. 37:5017-5017
5017 Background: Docetaxel and cabazitaxel represent now the standard of care in men with mCRPC with similar efficacy reported in metastatic first-line setting in the FIRSTANA phase 3 trial. We assessed patients’ preference between the two taxanes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30a0d31d9647904a7f3927004b311777
https://doi.org/10.1200/jco.2019.37.15_suppl.5017
https://doi.org/10.1200/jco.2019.37.15_suppl.5017
Autor:
Geraldine Martineau, Stéphanie Foulon, Giulia Baciarello, Florence Joly, Remy Delva, Philippe Barthelemy, Yann Neuzillet, Franck Priou, Anne Sophie Hue, Karim Fizazi
Publikováno v:
Journal of Clinical Oncology. 37:TPS334-TPS334
TPS334 Background: In recent years, the treatment of mCRPC has evolved and next-generation androgen receptor (AR)-axis targeting drugs (enzalutamide (ENZ), and abiraterone) have been approved and are routinely used. Darolutamide (DARO) is a new next-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a105f50749cc853118c3bfd11e276f2
https://doi.org/10.1200/jco.2019.37.7_suppl.tps334
https://doi.org/10.1200/jco.2019.37.7_suppl.tps334
Autor:
T. Nguyen Tan Hon, Geraldine Martineau, Y. Tazi, G. Gravis, Marine Gross-Goupil, P. Beuzeboc, Aude Flechon, M. Deblock, Remy Delva, Christine Theodore, Tifenn Lharidon, F. Joly Lobbedez, Giulia Baciarello, Isabelle Borget, Caroline Cheneau, Philippe Barthélémy, Stéphane Culine, J.-F. Berdah, Karim Fizazi, E. Bompas
Publikováno v:
Web of Science
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cee688bc627d0f336047c1d365d3af95
https://doi.org/10.1093/annonc/mdx370.019
https://doi.org/10.1093/annonc/mdx370.019
Autor:
Pernelle Lavaud, J. F. Berdah, Florence Joly, Carole Helissey, Karim Fizazi, Yohann Loriot, Nadia Zaghdoud, Geraldine Martineau, Stéphanie Foulon, Giulia Baciarello, Jean-Christophe Eymard, Anne Sophie Hue
Publikováno v:
Journal of Clinical Oncology. 36:TPS5093-TPS5093
TPS334Background: In recent years, the treatment of mCRPC has evolved and next-generation androgen receptor (AR)-axis targeting drugs (enzalutamide (ENZ), and abiraterone) have been approved and ar...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e373049b55eb5ed186b2f6c2a3f30e6
https://doi.org/10.1200/jco.2018.36.15_suppl.tps5093
https://doi.org/10.1200/jco.2018.36.15_suppl.tps5093
Autor:
Renate Arnold, Merav Leiba, François Guilhot, Marc Renaud, Geraldine Martineau, Michael Schleuning, Avichai Shimoni, E. Ribakovski, P. le Coutre, Arnon Nagler, Maya Koren-Michowitz
Publikováno v:
Leukemia. 23:190-194
Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia posi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93dca0c0ad3b3e16f7261ab448d350f2
https://doi.org/10.1038/leu.2008.160
https://doi.org/10.1038/leu.2008.160
Publikováno v:
Clinical lymphomamyeloma. 7
Chronic myelogenous leukemia is one of the leukemic disorders more responsive to immunotherapy. Interferon-based regimens were the first treatment to produce complete cytogenetic responses, and this agent has been classified as an immunotherapeutic a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f864207ee87c3b8c3630347cb1c66428
https://pubmed.ncbi.nlm.nih.gov/17382015
https://pubmed.ncbi.nlm.nih.gov/17382015